

Kymriah® (Tisagenlecleucel) Prior Authorization Form

Member Name: _____ Date of Birth: _____ Member ID#: _____

Drug Information

Physician billing (HCPCS code: _____) Pharmacy billing (NDC: _____)

Dose: _____ Regimen: _____ Start Date (or date of next dose): _____

Billing Provider Information

Provider NPI: _____ Provider Name: _____

Provider Phone: _____ Provider Fax: _____

Prescriber Information

Prescriber NPI: _____ Prescriber Name: _____

Prescriber Phone: _____ Prescriber Fax: _____ Specialty: _____

Criteria

*For Authorization: (approvals will be for 1 dose per member per lifetime)

1. Please include the most recent office visit note or clinical summary from the hospital to support your request.

Is this information attached? Yes ___ No ___

2. Is the health care facility on the certified list to administer CAR T-cells? Yes ___ No ___

3. Is the health care facility trained in the management of cytokine release syndrome (CRS) and neurologic toxicities? Yes ___ No ___

4. Will the health care facility comply with the Kymriah® REMS Program requirements? Yes ___ No ___

5. Please indicate the diagnosis and information:

Acute Lymphoblastic Leukemia (ALL)

A. Is diagnosis B-Cell precursor ALL? Yes ___ No ___

B. Is diagnosis Philadelphia chromosome negative (Ph-) ALL? Yes ___ No ___

C. Is diagnosis Philadelphia chromosome positive (Ph+) ALL? Yes ___ No ___

i. If Ph+ ALL, has member failed two or more Tyrosine Kinase Inhibitors (TKIs)?
Yes ___ No ___

ii. Please list previously failed TKIs: _____

D. Is ALL refractory or relapsed? Yes ___ No ___

i. If relapsed, please specify number of relapses: _____

Please provide additional information regarding previous therapies member has tried and failed:

Lymphoma

A. Is diagnosis large B-cell lymphoma [including diffuse large B-cell lymphoma (DLBCL), high grade B-cell lymphoma, and DLBCL arising from follicular lymphoma (FL)] or follicular lymphoma?
Yes ___ No ___

B. Does member have primary central nervous system lymphoma? Yes ___ No ___

C. Is disease status refractory or relapsed after 2 or more lines of therapy? Yes ___ No ___

D. Please provide additional information regarding previous therapies member has tried and failed:

If answer is none of the above, please indicate diagnosis: _____

Prescriber Signature: _____ Date: _____

I certify that the indicated treatment is medically necessary and all information is true and correct to the best of my knowledge. Please do not send in chart notes. Specific information will be requested if necessary. Failure to complete this form in full and attach requested clinical notes will result in processing delays.

CONFIDENTIALITY NOTICE

This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.

Fax completed prior authorization request form to 888-601-8461 or submit Electronic Prior Authorization through CoverMyMeds® or SureScripts. All requested data must be provided. Incomplete forms or forms without the chart notes will be returned. Pharmacy Coverage Guidelines are available at AetnaBetterHealth.com/Oklahoma.